Abstract des Autors

The purpose of this study was to evaluate the effect of the beta2-agonist albuterol (salbutamol) at twice the normal dosage (360 micro-g) on power output during a 30-second Wingate test and pulmonary function in highly trained cyclists (4 category I and 10 category II U.S.C.F. track cyclists). The cyclists did not have a history of exercise induced bronchial spasms, and a 5 step methacholine challenge confirmed all subjects to be non-asthmatic. The project was performed in a random block, double blind design. Twenty minutes before the 30-second Wingate cycle ergometer exercise, albuterol (90 micro-g per dose) or a saline placebo was administered by inhaler in 4 metered doses. Pulmonary function tests were performed at rest, 20 minutes post-inhalation, and 5, 10, 15 minutes post-exercise. After a standard warm-up, a 30-second Wingate anaerobic power test was performed on a cycle ergometer at a resistance of 0.10 kg/(kg body mass). Multi-variate ANOVA revealed no significant difference between the albuterol and placebo treatment for the anaerobic power measures: peak power, total work, time to peak power, and fatigue indes. Peak heart rate (181.6+/-3.7 vs 181.4+/-3.8 bpm), or blood lactate (14.0+/-0.9 vs 13.8+/-0.8 mmol/l) 3 min after the exercise bout were not significantly different between treatments. FEV1, FEF25-75%, and PEF were significantly higher after albuterol administration as compared to the placebo trail after inhalation and post-exercise at several time points. There was no significant difference for the albuterol as compared to the placebo trial for FVC. The data indicate that in non-asthmatic, well trained cyclists anaerobic power measures during a 30-second Wingate anaerobic power test are not affected. However, pulmonary function measures may be enhanced due to administration of albuterol. Verf.-Referat